Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Trastuzumab deruxtecan (T-DXd) is an approved therapy for non-small cell lung cancer (NSCLC) in China. Despite the clinical trial evidence, there is no real-world data of T-DXd used in Chinese lung cancer patients with HER2 mutations. This real world, prospective study will assess the effectiveness and safety of T-DXd in patients with locally advanced or metastatic, HER2 mutation-positive NSCLC in real-world setting.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony rozpoznaniem nierdzenia raka płuc niezdatny do operacji lub z przerzutami
- •Stwierdzenie mutacji genu HER2
- •Dobry stan zdrowotny pacjenta (ocena wydolności 0-2)
- •Pacjent rozpoczyna leczenie trastuzumab deruxtecan (nowe lub w ciągu ostatnich 2 miesięcy)
✗ Disqualifies
- •Wcześniejsze leczenie terapiami ukierunkowanymi na HER2 (za wyjątkiem określonych leków z grupy pan-HER)
- •Wcześniejsze leczenie innym podobnym lekiem chemioterapeutycznym (ADC z inhibitorem topoisomerazy I)
- •Przerzuty do mózgu lub rdzenia kręgowego powodujące objawy, jeśli nie są leczone
- •Poważne niekontrolowane choroby układowe, takie jak niekontrolowane ciśnienie krwi lub zaburzenia krwawienia
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 18, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (36)
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, China
The History of Beijing Tiantan Hospital, Capital Medical University
Beijing, China
Peking University International Hospital
Beijing, China
Beijing Cancer Hospital
Beijing, China
Peking University Third Hospital
Beijing, China
Beijing Chest Hospital, Capital Medical University
Beijing, China
Hunan Second People's Hospital
Changsha, China
Fujian Cancer Hospital
Fuzhou, China
Dongguan People's Hospital
Guangdong, China
Affiliated Cancer Hospital and Institute of Guangzhou Medical University
Guangzhou, China
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, China
Zhejiang Cancer Hospital
Hangzhou, China
Cancer Hospital Chinese Academy of Medical Sciences （Langfang Section)
Hebei, China
Anhui Provincial Cancer Hospital
Hefei, China
Hubei Cancer Hospital
Hubei, China
Nanjing Drum Tower Hospital
Jiangsu, China
Affiliated Hospital of Nantong University
Jiangsu, China
Jiangxi Cancer Hospital
Jiangxi, China
First Affiliated Hospital of Shandong First Medical University
Jinan, China
Cancer Hospital of Shandong First Medical University
Jinan, China
The First Affiliated Hospital of Jinzhou Medical University
Jinzhou, China
The First Affiliated Hospital of Nanchang University
Nanchang, China
Guangxi Medical University Cancer Hospital
Nanning, China
The Affiliated Hospital of Qingdao University
Shandong, China
Ruijin Hospital, Shanghai Jiaotong University School Of Medicine
Shanghai, China
Zhongshan Hospital Fudan University
Shanghai, China
Shanghai Pulmonary Hospital
Shanghai, China
Shanghai Geriatric Medical Hospital
Shanghai, China
The First Hospital of China Medical University
Shenyang, China
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center
Shenzhen, China
The Fourth Hospital of Hebei Medical University
Shijiazhuang, China
Shangxi Provincial Cancer Hospital
Taiyuan, China
The First Affiliated Hospital of Xiamen University
Xiamen, China
The Second Affiliated Hospital Zhejiang University School of Medicine
Zhejiang, China
Henan Cancer Hospital
Zhengzhou, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China
Trial contact
Contact for Clinical Trial Information
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/19/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.